Profile: Calibrant Biosystems, Inc. focuses on the development of novel therapeutics using the Gemini™ discovery engine to elucidate disease pathways and protein networks from targeted cells captured from clinical tissue specimens. Our Gemini™ platform enables comprehensive and quantitative protein profiling of isolated & homogeneous cell populations from both fresh & archival formalin-fixed tissues, allowing to approach the full biology of disease pathogenesis with exquisite sensitivity. Our protein biomarkers offer great potential for streamlining preclinical trials by aiding in rapid decision making, and can reduce clinical trial costs through effective patient enrichment, narrowing the patient population while reducing the likelihood for late-stage failures.